CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 220 enrolled
Drug / intervention
Ocriplasmin +1 moredrug
Likely dose
Ocriplasmin 0.125 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01429441
NCT01429441Phase 3Completed
CompareCT.gov

A Randomized, Sham-controlled, Double-masked, Multicenter Study Evaluating Ocriplasmin Treatment for Symptomatic Vitreomacular Adhesion Including Macular Hole

ThromboGenics·interventional·Posted Sep 7, 2011·Updated Mar 14, 2016

In Brief

A Phase 3 clinical trial evaluating Ocriplasmin and Sham injection for Vitreomacular Adhesion Including Macular Hole. Completed, enrolled 220 participants across 25 sites.

Detailed Summary

The purpose of this study is to evaluate the treatment of symptomatic vitreomacular adhesion / (VMT) including macular hole with ocriplasmin.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsVitreomacular Adhesion Including Macular Hole
CountriesUnited States
Collaborators--

Timeline

Phase 3CompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedSep 7, 2011
Enrollment StartOct 1, 2011
Primary CompletionOct 1, 2014
TodayJul 2, 2026
Enrollment to primary: 3 yearsPosted 14.8 years ago

Interventions

Ocriplasmindrug

0.125 mg single intravitreal injection

Sham injectionother

Sham injection